Impact News +++ Palantir stock plummets 20% from highs in longest losing streak since April 2024 (CNBC) +++ PALANTIR Aktie +3,58%

BIOXCEL Aktie

>BIOXCEL Aktienkurs

4.07 EUR -3.4% (Tradegate)

Ask: 4.025 EUR / 750 Stück

Bid: 3.925 EUR / 770 Stück

Tagesumsatz: 9068 Stück

Realtime Kurs von 8 bis 22 Uhr!

BIOXCEL Aktie über LYNX handeln

Intraday

1 Jahr

>BIOXCEL Performance

1 Woche: 0%

1 Monat: 0%

3 Monate: 0%

6 Monate: 0%

1 Jahr: 0%

laufendes Jahr: 0%

>BIOXCEL Aktie

Name:

BIOXCEL THERAPEUTICS

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US09075P2048 / A40YSR

Symbol/ Ticker:

BX20 (Frankfurt) / BTAI (NASDAQ)

Kürzel:

FRA:BX20, ETR:BX20, BX20:GR, NASDAQ:BTAI

Index:

Webseite:

https://www.bioxceltherap..

Profil:

Marktkapitalisierung:

70.69 Mio. EUR

Unternehmenswert:

148.09 Mio. EUR

Umsatz:

0.74 Mio. EUR

EBITDA:

-41.78 Mio. EUR

Nettogewinn:

-43.64 Mio. EUR

Gewinn je Aktie:

-10.85 EUR

Schulden:

93.31 Mio. EUR

Liquide Mittel:

15.91 Mio. EUR

Operativer Cashflow:

-47.76 Mio. EUR

Bargeldquote:

0.56

Umsatzwachstum:

-63.88%

Gewinnwachstum:

52.75%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

BIOXCEL

Letzte Datenerhebung:

20.08.25

>BIOXCEL Kennzahlen

Aktien/ Unternehmen:

Aktien: 14.56 Mio. St.

Frei handelbar: 90.72%

Leerverk. Aktien: 8.56%

Rückkaufquote: -24.98%

Mitarbeiter: 37

Umsatz/Mitarb.: 0.05 Mio. EUR

Analysten:

Analystenrating: Buy

Kursziel: 242.15%

Bewertung:

KGV: -

KGV lG: -

KUV: 49.52

KBV: -

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: -179.72%

Gewinnmarge: -5869.82%

Operative Marge: -5655.41%

Managementeffizenz:

Gesamtkaprendite: -111.7%

Eigenkaprendite: -

>BIOXCEL Peer Group

Es sind 601 Aktien bekannt.

>BIOXCEL Chart & Kurs - NASDAQ

>BIOXCEL News

19.08.25 - 13:03	BioXcel Therapeutics Announces Database Lock in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia (GlobeNewswire EN)
	Data from more than 2,600 agitation episodes collected...

18.08.25 - 13:03	BioXcel Therapeutics Announces Positive FDA Pre-sNDA Meeting Comments for sNDA Submission for BXCL501 in Agitation Associated with Bipolar Disorders or Schizophrenia (GlobeNewswire EN)
	Achieved alignment with the FDA on sNDA package to expand the IGALMI label for the At-Home (Outpatient) setting...

18.08.25 - 12:01	XFRA: BX20: Wiederaufnahme/Resumption (XETRA)
	FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE. THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIOXCEL THERAP.INC.NEW BX20 US09075P2048 AB/FROM ONWARDS 18.08.2025 11:54 CET...

16.08.25 - 15:45	BTAI Delivers Over 300% In Less Than 2 Months - SERENITY At-Home Trial Data Due This Month (RTTNews)
	BioXcel Therapeutics Inc. (BTAI) has a clinical trial catalyst to watch this month, related to its lead drug, IGALMI, in an expanded indication....

13.08.25 - 13:03

BioXcel Therapeutics to Participate in the H.C. Wainwright & Co. “HCW@Home” Series (GlobeNewswire EN)

NEW HAVEN, Conn., Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics, will participate in a virtual fireside chat on Thursday, August 14, 2025 at 1:00 p.m. ET as part of the H.C. Wainwright & Co. “HCW@Home” series....

12.08.25 - 22:45	BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
	BioXcel Therapeutics (BTAI) delivered earnings and revenue surprises of -6.52% and -52.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?...

12.08.25 - 14:03	BioXcel Therapeutics GAAP EPS of -$2.45 misses by $0.59, revenue of $0.12M misses by $0.09M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

12.08.25 - 13:57	BioXcel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates (GlobeNewswire EN)
	Topline data from SERENITY At-Home Phase 3 trial for acute treatment of agitation associated with bipolar disorders or schizophrenia expected in August...

06.08.25 - 13:03	BioXcel Therapeutics Announces Publication in Frontiers in Pharmacology on the Effects of Dexmedetomidine (the active ingredient in BXCL-501) on Stress-Mediated Behaviors in Non-clinical Studies (GlobeNewswire EN)
	Dexmedetomidine demonstrated a significant reduction in stress-induced behaviors, suggesting potential applications of BXCL501 in chronic psychiatric disorders in addition to treatment of acute agitation...

01.08.25 - 13:03	BioXcel Therapeutics Announces Last Patient Last Visit in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia (GlobeNewswire EN)
	Vast majority of patients dosed completed the full 12-week study...

21.07.25 - 13:03	BioXcel Therapeutics Submits Pre-Supplemental New Drug Application Meeting Package in Support of Potential Label Expansion for IGALMI® (GlobeNewswire EN)
	Company focused on obtaining approval for outpatient (at-home) use of IGALMI® for the acute treatment of agitation associated with bipolar disorders or schizophrenia...

01.07.25 - 13:03	BioXcel Therapeutics Receives Second Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia (GlobeNewswire EN)
	DSMB recommended the continuation of trial as planned...

27.05.25 - 14:06	BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia (GlobeNewswire EN)
	DSMB recommended the continuation of trial as planned...

27.05.25 - 13:24	BioXcel Therapeutics gets extension from Nasdaq to regain compliance (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

27.05.25 - 13:03	BioXcel Therapeutics Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirement (GlobeNewswire EN)
	NEW HAVEN, Conn., May 27, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that the Nasdaq Hearings Panel granted the Company's request to continue its listing on The Nasdaq Stock Market....

12.05.25 - 16:00	BioXcel Therapeutics, Inc. (BTAI) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
	BioXcel Therapeutics (BTAI) delivered earnings and revenue surprises of 44.85% and 44%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?...

12.05.25 - 13:21	BioXcel Therapeutics GAAP EPS of -$1.50 beats by $1.54, revenue of $0.17M misses by $0.18M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

12.05.25 - 13:03	BioXcel Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire EN)
	Enrollment complete in SERENITY At-Home pivotal Phase 3 safety trial for acute treatment of agitation associated with bipolar disorders or schizophrenia...

27.03.25 - 15:01	BioXcel Therapeutics, Inc. (BTAI) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
	BioXcel Therapeutics (BTAI) delivered earnings and revenue surprises of 18.12% and 144%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?...

27.03.25 - 12:12	BioXcel Therapeutics GAAP EPS of -$3.57 beats by $3.37, revenue of $0.37M misses by $0.35M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Am Anfang war die Kraft. - Paula Modersohn-Becker

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram